Is there a role for anti-IL5 therapy in the treatment of EoE?

When looking at the use of IL-5 pathway drugs such as mepolizumab, reslizumab, and benralizumab in the treatment of eosinophilic esophagitis (EoE) studies to date have not demonstrated efficacy in terms of symptomatic improvement as related to the use of these series of medications. Each of these medications has achieved control of esophageal eosinophilia absent improvement in symptomatology.

In general, I would not consider IL-5 pathway drugs and would consider the use of dupilumab if other the...